Dr. Mark Sulkowski

Dr. Chloe Thio is a professor of medicine and an associate professor of molecular microbiology and immunology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include hepatitis, HIV/AIDS and infectious disease. Dr. Thio received her B.A. from the University of Pennsylvania. She earned her M.D. from the Yale University School of Medicine. She completed her residency at Hospital of the University of Pennsylvania and her fellowship in infectious diseases at Johns Hopkins. Her research interests include chronic hepatitis B and C and coinfection of viral hepatitis with HIV/AIDS. She has developed a program centered around virology and immunology translational work towards an HBV cure. Dr. Thio is a member of the American College of Physicians, the American Association for the Study of Liver Disease, the American Society of Clinical Investigation, HIVMA and the Infectious Diseases Society of America. Dr. Thio is rated as a Distinguished provider by MediFind in the treatment of Hepatitis B. Her top areas of expertise are Hepatitis, Hepatitis B, Hepatitis C, and HIV/AIDS.

Lydia Tang is an Infectious Disease provider in Baltimore, Maryland. Dr. Tang is rated as an Advanced provider by MediFind in the treatment of Hepatitis B. Her top areas of expertise are Hepatitis, Hepatitis B, Hepatitis C, and Liver Failure. Dr. Tang is currently accepting new patients.

Dr. Gregory Kirk is a professor of medicine at the Johns Hopkins University School of Medicine. He holds joint appointments in oncology and, at the Johns Hopkins Bloomberg School of Public Health, in epidemiology. His areas of clinical expertise include epidemiology, hepatitis, HIV, AIDS and infectious diseases. He serves as the vice chair for clinical and translational research at the Johns Hopkins School of Medicine. Dr. Kirk received his undergraduate degree from Oklahoma State University. He earned a Ph.D. and M.P.H. from the Johns Hopkins Bloomberg School of Public Health. He earned his M.D. from the University of Oklahoma Health Sciences Center College of Medicine. He completed a residency in preventative medicine at the Johns Hopkins Bloomberg School of Public Health and in internal medicine at Georgetown University. He performed a fellowship in infectious diseases at the National Institute of Allergy and Infectious Diseases. His research focuses on understanding and preventing the long-term consequences of chronic HIV infection, particularly the malignant complications of HIV and viral hepatitis. He has extensive research and clinical experience in Africa, leading the Gambia Liver Cancer Study, one of the largest studies of hepatocellular carcinoma (HCC) performed in the continent, in addition to years of collaborative research in Uganda. Dr. Kirk pioneered the use of elastography and application of novel aflatoxin-associated biomarkers of HCC risk to be applied in Consortium projects. He has strong, multidisciplinary team leadership skills as principal investigator of the ALIVE cohort and several other collaborative studies in Baltimore. Dr. Kirk is rated as a Distinguished provider by MediFind in the treatment of Hepatitis B. His top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, and Hepatitis B.